The EMJ Podcast | Bonus Episode
In this episode, moderator George Cooper, sits down with the brilliant minds of Professor Stacey Cohen and Dr. Jeff Sharman. Together, they delve into the fascinating world of Monoclonal Antibody Biosimilars and their significant impact on the field of Oncology, with a particular focus on Lymphoma and Colorectal Cancer.
Spotify | Apple | Amazon Music | Download MP3 (mp3, 27:32 mins)
Join us as our expert panel explores the utilization of Monoclonal Antibody Biosimilars in the treatment of these cancers, shedding light on their efficacy and safety. Drawing from their extensive experience and knowledge, Professor Cohen and Dr. Sharman also share their insights on the prevailing attitudes towards this approach, while highlighting the key aspects of the current consensus within the medical community. This episode also offers a glimpse into the future prospects of Monoclonal Antibody Biosimilars, including the anticipated uptake and potential advancements in the field.
Professor Stacey Cohen
Associate Professor at the Clinical Research Division, Fred Hutch Cancer Centre as well as an Associate Professor at the Division of Oncology, University of Washington.
Professor Cohen is a specialized medical oncologist focusing on GI cancers, including colon, rectal, early-onset, and hereditary types. Her research explores the influence of genetics on treatment choices, encompassing hereditary gene alterations, tumor genetic changes, and novel disease markers. Dr. Cohen aims to personalize treatment decisions for her patients and the wider cancer community, maximizing efficacy while minimizing side effects. She values establishing enduring patient relationships and participating in collaborative decision-making processes.
Doctor Jeff P Sharman
Director of Research at the Willamette Valley Cancer Institute as well as the Medical Director of Hematology Research for The US Oncology Network.
Dr. Sharman, the research director at the Willamette Valley Cancer Institute and the medical director of hematology research for The US Oncology Network, possesses extensive knowledge and expertise in the latest scientific advancements across various cancer types. His notable contributions to treatment progress and extensive publication history in esteemed scientific journals, such as the New England Journal of Medicine, Journal of Clinical Oncology, and Blood, highlight his expertise. Through his research program in Eugene, he has garnered global recognition in diverse cancer fields and presented his findings at major conferences in the US, Asia, and Europe. Dr. Sharman’s research has facilitated WVCI’s access to exciting new areas of research, including immunotherapy, targeted therapy, and personalized medicine.
This podcast was funded by an educational grant from Pfizer, who has had no input to the creation of this educational podcast.
